Sun Pharma ends patent dispute with Actavis

Sun Pharmaceutical has announced its US subsidiary, Ranbaxy Pharmaceuticals, and other partners have entered into a settlement, ending the patent litigation with drug maker Actavis over anti-acne......

Ranbaxy provisions for settlement with US

Ranbaxy Laboratories, undergoing an import ban imposed by America’s drug regulator on the company’s four Indian factories, has made a one-time provision in its April-June financial......

Ranbaxy sets aside Rs 257.4 cr for impact of USFDA ban

Pharma major Ranbaxy Laboratories has set aside Rs 257.4 crore (Rs 2.57 billion) towards the financial impact of a US ban on import of products made at its plant at Toansa. In January, the US Food......

Watson sends patent challenge notice to Ranbaxy for acne drug

Ranbaxy Laboratories has said its US arm has received a notice from Watson Laboratories Inc, challenging the patent of acne treatment drug Absorica. The drug is licensed to Ranbaxy Laboratories......